Company Overview

Coeptis Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapy and immuno-oncology treatments. The company operates within the biotechnology and life sciences industries, with an emphasis on addressing cancers and immune-mediated diseases through advanced cellular engineering approaches. Its strategy centers on leveraging differentiated cell therapy platforms intended to improve efficacy, safety, and scalability compared with existing therapies.

The company’s core value proposition lies in its development of allogeneic and autologous cell therapy candidates, targeting both oncology and immune disorders. Coeptis Therapeutics traces its origins to earlier private biotechnology operations and became a publicly traded entity through a reverse merger transaction, subsequently rebranding to its current name. Since becoming public, the company has repositioned its pipeline and corporate structure to focus on cell-based immunotherapies, while maintaining a lean operational model typical of early-stage biotech firms.

Business Operations

Coeptis Therapeutics generates no commercial revenue and operates as a development-stage company, with activities centered on research, preclinical development, clinical planning, and intellectual property management. Its primary operating focus is the advancement of proprietary cell therapy platforms, including natural killer (NK) cell-based and other immune cell approaches designed to target cancer cells while reducing toxicity risks associated with traditional therapies.

Operations are primarily conducted through the parent company and its wholly owned subsidiaries, including Coeptis Therapeutics, Inc., which holds the majority of the company’s intellectual property assets. Research and development activities are supported through a combination of internal scientific leadership, contract research organizations, and academic or clinical collaborators. Based on publicly available filings, no material manufacturing facilities are owned by the company, and development activities rely heavily on third-party service providers.

Strategic Position & Investments

Strategically, Coeptis Therapeutics is positioned as an early-stage platform company, seeking to validate its technologies through preclinical and early clinical milestones before pursuing partnerships, licensing arrangements, or additional capital raises. Growth initiatives focus on advancing lead programs into clinical evaluation, expanding the intellectual property estate, and identifying complementary assets or technologies that align with its immunotherapy focus.

The company has pursued targeted acquisitions and asset purchases to strengthen its pipeline, including the acquisition of intellectual property and development rights related to cell therapy technologies. Public disclosures indicate that management continues to evaluate strategic transactions, though details on future acquisitions or large-scale investments remain limited. Where specific timelines or outcomes are discussed, available public sources indicate that development progress remains subject to regulatory review and financing conditions, and some details are data inconclusive based on available public sources.

Geographic Footprint

Coeptis Therapeutics is headquartered in the United States, with its principal executive offices located in New York. The company’s operational footprint is predominantly domestic, reflecting its early-stage development status and reliance on U.S.-based regulatory pathways.

International exposure is currently limited and primarily indirect, arising from relationships with global service providers, scientific collaborators, or intellectual property protections filed in multiple jurisdictions. The company does not report significant overseas facilities or revenue-generating international operations, though future clinical trials or partnerships could expand its global presence.

Leadership & Governance

Coeptis Therapeutics is led by a management team with experience in biotechnology development, corporate strategy, and public company governance. Leadership emphasizes disciplined capital allocation, platform-driven innovation, and advancing cell therapy candidates through clearly defined development milestones. Governance follows standard public-company practices, with oversight provided by a board of directors and adherence to U.S. securities regulations.

Key executives include:

• Dave Mehalick – Chief Executive Officer
• Mark S. Mastandrea – Chief Financial Officer
• Charles J. Nicolette – Chief Scientific Officer
• John L. Wysong – President and Director

The leadership team’s stated strategic vision focuses on building long-term value through differentiated immunotherapy platforms while maintaining operational flexibility and regulatory compliance as the company progresses through clinical development stages.